Minimize Rheumatoid Arthritis Costs and Intensive Treatments By Engaging Patients

At PAINWeek 2014, patient engagement was termed the “blockbuster drug for pain” by faculty member Barbara Kornblau, JD, OTR/L, CPE, DASPE. Recent affirmation of the concept is provided by new research published in the journal Rheumatology reporting that patients with rheumatoid arthritis scored poorly in adherence to prescribing instructions for their biological medications. The UK-based study found that despite the proven effectiveness of new biologic drugs such as anti-TNF therapy, some 40% of patients fail to take the medications regularly as prescribed. The findings have prompted Arthritis Research UK’s head of health promotion to encourage people with arthritis to seek out further information and advice so that they are able to better understand the medication they have been prescribed, its positive benefits for their condition, and the reasons for taking it as directed.

Among reasons cited by the researchers for this patient behavior were concern over potential side effects, a failure to appreciate the chronic nature of their illness, and a paucity of professional and/or family support. The team advocates a concentrated effort to inform, support, and engage patients more intensively, as a cost effective means to minimize the need for further intensive treatments and reduce unnecessary wastage of these expensive drugs.

For more about patient engagement:

For an interview with Barbara Kornblau, mentioned above, click here.

To read about a patient engagement and provider communication study of opioid therapy, click here.

For more about rheumatoid arthritis, click here.

Read more on the research findings discussed above, with link to the source article, here.



Related Content